Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.66 |
| ▸ | NAAA | Q02083 | 14/20 | 0.57 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11480550 | 0.98 | EPHX1 (0.64) | EPHX1NAAAASAH1SMN1; SMN2FKBP1A | |
| SCHEMBL11480555 | 0.90 | EPHX1 (0.59) | EPHX1NAAAASAH1SMN1; SMN2 | |
| SCHEMBL11698289 | 0.89 | EPHX1 (0.51) | EPHX1NAAAASAH1SMN1; SMN2 | |
| SCHEMBL27842415 | 0.86 | EPHX1 (0.49) | EPHX1NAAAASAH1SMN1; SMN2 | |
| SCHEMBL28327948 | 0.86 | EPHX1 (0.58) | EPHX1NAAAASAH1SMN1; SMN2FKBP1A | |
| SCHEMBL8894885 | 0.86 | EPHX1 (0.58) | EPHX1NAAAASAH1SMN1; SMN2FKBP1A | |
| SCHEMBL8896214 | 0.84 | EPHX1 (0.56) | EPHX1NAAAASAH1SMN1; SMN2FKBP1A | |
| SCHEMBL1734362 | 0.84 | EPHX1 (0.46) | EPHX1NAAAASAH1SMN1; SMN2 | |
| SCHEMBL11695254 | 0.84 | SMN1; SMN2 (0.49) | EPHX1NAAAASAH1SMN1; SMN2FKBP1A | |
| SCHEMBL28326644 | 0.84 | EPHX1 (0.55) | EPHX1NAAAASAH1SMN1; SMN2FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069539-A1 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | POSEIDA THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4652153-A1 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | Poseida Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024155938-A1 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | POSEIDA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069539-A1 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | STARD3, LPCAT3, LPCAT1 | EPHX1 2808/4885NAAA 3421/4885ASAH1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.